OncoMatch/Clinical Trials/NCT07213609
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Is NCT07213609 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GSK5460025 for neoplasms, colorectal.
Treatment: GSK5460025 — Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immune checkpoint inhibitor — advanced disease
including at least one line of Immune checkpoint inhibitors (ICI) therapy
Must have received: systemic anticancer therapy — advanced disease
Has received at least 1 but no more than 3 lines of systemic anticancer therapy for their advanced (unresectable, metastatic or recurrent) disease
Cannot have received: Werner inhibitor
Has received prior treatment with a Werner (WRN) inhibitor
Cannot have received: Nucleotide Excision Repair Targeting agent
Has received prior treatment with...Nucleotide Excision Repair Targeting (NERT) agent
Lab requirements
Blood counts
Kidney function
Liver function
Has adequate organ function, as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Canton, Ohio
- GSK Investigational Site · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify